Download Files:
Ravoxertinib hydrochloride
$96 – $360
Products Details
Product Description
– Ravoxertinib hydrochloride (GDC-0994 hydrochloride) is an orally bioavailable inhibitor selective for ERK kinase activity with IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively.
Web ID
– HY-15947A
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C21H19Cl2FN6O2
Citations
– ACS Omega. 2023 May 23.|Nucleic Acids Res. 2022 Apr 8;50(6):3096-3114.|Pathol Res Pract. December 2021, 153682.|ACS Comb Sci. 2019 Dec 9;21(12):805-816.|Am J Cancer Res. 2020 Nov 1;10(11):3622-3643.|Am J Physiol Heart Circ Physiol. 2018 Mar 1;314(3):H580-H592.|Biochem Biophys Res Commun. 2021 Mar 26;554:63-70.|Cancer Cell. 2023 Jul 10;41(7):1345-1362.e9.|Cancer. 2020 Mar 15;126(6):1339-1350.|Cancers (Basel). 2022 Mar 19;14(6):1575.|Cancers (Basel). 2022 May 19;14(10):2493.|Cell Death Dis. 2021 Dec 1;12(12):1123.|Cell Mol Immunol. 2023 Jan 5.|Cell Rep. 2023 Sep 1;42(9):113048.|Cell Signal. 2023 Jan 20;110607.|Cell. 2018 Sep 20;175(1):186-199.e19.|Clin Transl Med. 2023 Aug;13(8):e1381.|Diabetes. 2021 Jun 21;db200719.|Environ Pollut. 2021 Jan 1;268(Pt B):115748.|Exp Mol Pathol. 2021 Feb;118:104587.|Gastric Cancer. 2023 Feb 22.|Harvard Medical School LINCS LIBRARY|Indian J Pharm Sci. 2022.|Int J Med Sci. 2022 Jan 1;19(1):195-204.|J Cell Biochem. 2020 Mar;121(3):2343-2353.|J Cell Mol Med. 2020 Sep;24(17):10151-10165.|J Exp Clin Cancer Res. 2023 Jul 13;42(1):166.|J Pharmacol Exp Ther. 2020 Jul;374(1):104-112.|Methods Mol Biol. 2018;1711:351-398.|Mol Oncol. 2020 Nov;14(11):2894-2919.|Nat Commun. 2023 Sep 30;14(1):6117.|Nat Metab. 2022 Mar;4(3):374-388.|Neural Regen Res. 2023.|Oncogene. 2021 Jul;40(30):4884-4893.|Proteomics. 2023 May 4;e2300041.|Redox Biol. 2023 Jul 24, 102825.|Reprod Sci. 2020 Feb;27(2):704-712.|Sci Transl Med. 2021 Jan 27;13(578):eaba7308.|Toxicol In Vitro. 2020 Jun;65:104777.|Universität Würzburg. Graduate School of Life Sciences. 2021 Jan.|Zool Res. 2022 Jul 18;43(4):537-551.
References
– [1]MICHAEL LAI. Opportunity for Pharmaceutical Intervention in Lung Cancer: Selective Inhibition of JAK1/2 to Eliminate EMT-Derived Mesenchymal Cells.|[2]Kirk Robarge, et al. Abstract DDT02-03: Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development. Proceedings: AACR Annual Meeting 2014; April 5-9, 2014.|[3]Blake JF, et al. Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Developme
CAS Number
– 2070009-58-2
Molecular Weight
– 477.32
Compound Purity
– 99.93
SMILES
– O=C1C=C(C2=NC(NC3=CC=NN3C)=NC=C2)C=CN1[C@@H](C4=CC=C(Cl)C(F)=C4)CO.Cl[H]
Clinical Information
– Phase 1
Research Area
– Cancer
Solubility
– DMSO : 100 mg/mL (ultrasonic)|H2O : 1 mg/mL (ultrasonic;warming;heat to 80°C)
Target
– ERK
Isoform
– ERK1;ERK2
Pathway
– MAPK/ERK Pathway;Stem Cell/Wnt
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
